drugset / Trial / NCT03838484

Effects of Transdermal Nicotine on Response Inhibition to Emotional Cues in Schizophrenia

NCT03838484

RandomizedCrossoverQuadruple-blindBasic science

Summary

The purpose of this study is to test whether nicotine, a drug that activates receptors called nicotinic acetylcholine receptors in the brain, improves the ability to make or withhold responses to faces that are either emotionally neutral or emotionally negative. This study will also test whether the drug affects brain activity while making or withholding responses using electroencephalography. Previous studies in people with schizophrenia have shown that more errors in response to negative emotional cues are related to greater likelihood of impulsive aggressive behavior. Therefore, the aim of this study is to determine whether nicotine might be a new strategy to reduce aggressive behavior. The investigators' goal is 25 individuals with schizophrenia and 25 healthy controls to complete the study at Vanderbilt.

Timeline

Start
2019-05-10
Primary completion
2020-02-24
Completion
2020-02-24

Drugs

EvaluationDrugModalityDoseRoute
Subject Nicotine Unknown 7 mg Topical